Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism

J Pharm Pharmacol. 2009 Jan;61(1):47-54. doi: 10.1211/jpp/61.01.0007.

Abstract

Objectives: It has been reported that the non-renal clearance of furosemide was significantly faster in rats pretreated with phenobarbital but was not altered in rats pretreated with 3-methylcholanthrene. However, no studies on other cytochrome P450 (CYP) isozymes have yet been reported in rats.

Method: Furosemide 20 mg/kg was administered intravenously to rats pretreated with various CYP inducers--3-methylcholanthrene, orphenadrine citrate and isoniazid, inducers of CYP1A1/2, 2B1/2 and 2E1, respectively, in rats--and inhibitors--SKF-525A (a non-specific inhibitor of CYP isozymes), sulfaphenazole, cimetidine, quinine hydrochloride and troleandomycin, inhibitors of CYP2C6, 2C11, 2D and 3A1/2, respectively, in rats.

Key findings: The non-renal clearance of furosemide was significantly faster (55.9% increase) in rats pretreated with isoniazid, but slower in those pretreated with cimetidine or troleandomycin (38.5% and 22.7% decreases, respectively), than controls. After incubation of furosemide with baculovirus-infected insect cells expressing CYP2C11, 2E1, 3A1 or 3A2, furosemide was metabolized via CYP2C11, 2E1, 3A1 and 3A2.

Conclusions: These findings could help explain possible pharmacokinetic changes of furosemide in various rat disease models (where CYP2C11, 2E1, 3A1 and/or CYP3A2 are altered) and drug-drug interactions between furosemide and other drugs (mainly metabolized via CYP2C11, 2E1, 3A1 and/or 3A2).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Area Under Curve
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cimetidine / administration & dosage
  • Cimetidine / pharmacology
  • Cytochrome P-450 Enzyme System / metabolism*
  • Diuretics / administration & dosage
  • Diuretics / metabolism
  • Diuretics / pharmacokinetics
  • Drug Interactions
  • Enzyme Activators / administration & dosage
  • Enzyme Activators / pharmacology*
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / pharmacology*
  • Furosemide / administration & dosage
  • Furosemide / metabolism
  • Furosemide / pharmacokinetics*
  • Half-Life
  • Infusions, Intravenous
  • Injections, Intravenous
  • Isoniazid / administration & dosage
  • Isoniazid / pharmacology
  • Male
  • Methylcholanthrene / administration & dosage
  • Methylcholanthrene / pharmacology
  • Orphenadrine / administration & dosage
  • Orphenadrine / pharmacology
  • Proadifen / administration & dosage
  • Proadifen / pharmacokinetics
  • Quinine / administration & dosage
  • Quinine / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Troleandomycin / administration & dosage
  • Troleandomycin / pharmacology
  • Weight Gain / drug effects

Substances

  • Diuretics
  • Enzyme Activators
  • Enzyme Inhibitors
  • Methylcholanthrene
  • Furosemide
  • Cimetidine
  • Cytochrome P-450 Enzyme System
  • Proadifen
  • Quinine
  • Orphenadrine
  • Troleandomycin
  • Aryl Hydrocarbon Hydroxylases
  • Isoniazid